Abstract
BackgroundCurrently, potent P2Y12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have